Sage Journals: Discover world-class research

Abstract

Background:

The utility of blood–brain barrier (BBB) biomarkers for clinical and magnetic resonance imaging progression in multiple sclerosis (MS) has not been extensively investigated.

Objectives:

To determine whether cerebrospinal fluid (CSF) measures of BBB at clinical onset predict radiological and clinical deterioration over 48 months.

Methods:

This longitudinal study included 182 patients after first clinical event suggestive of MS treated with weekly intramuscular interferon beta-1a. CSF and serum samples were analyzed for leukocytes, total protein, albumin, immunoglobulins, and oligoclonal bands. Optimal thresholds for the albumin quotient (QAlb) were determined. Mixed-effect model analyses, adjusted for age, gender, and treatment escalation, were used to analyze relationship between CSF measures and disease activity outcomes over 48 months of follow-up.

Results:

Increased QAlb at clinical onset was associated with enlargement of lateral ventricles (p = .001) and greater whole brain (p = .003), white matter (p < .001), corpus callosum (p < .001), and thalamus (p = .003) volume loss over 48 months. Higher QAlb was associated with higher Expanded Disability Status Scale score over 48 months (p = .002).

Conclusions:

Increased QAlb at clinical onset is associated with increased brain atrophy and greater disability in patients after first clinical event suggestive of MS.

Keywords

Multiple sclerosis clinically isolated syndrome blood–brain barrier MRI brain atrophy disability

Get full access to this article

View all access options for this article.

References

Freedman

Thompson

Deisenhammer

. Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch Neurol 2005; 62: 865–870.

Deisenhammer

Bartos

Egg

. Guidelines on routine cerebrospinal fluid analysis. Report from an EFNS task force. Eur J Neurol 2006; 13: 913–922.

Werring

Brassat

Droogan

. The pathogenesis of lesions and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 2000; 123(Pt 8): 1667–1676.

Plumb

McQuaid

Mirakhur

. Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis. Brain Pathol 2002; 12: 154–169.

Cramer

Simonsen

Frederiksen

. Abnormal blood–brain barrier permeability in normal appearing white matter in multiple sclerosis investigated by MRI. Neuroimage Clin 2013; 4: 182–189.

Fabis

Scott

Kean

. Loss of blood–brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc Natl Acad Sci USA 2007; 104: 5656–5661.

Uher

Horakova

Kalincik

Bergsland

Tyblova

Ramasamy

Seidl

Vaneckova

Krasensky

Havrdova

Zivadinov

Early magnetic resonance imaging predictors of clinical progression after 48 months in clinically isolated syndrome patients treated with intramuscular interferon β-1a. Eur J Neurol 2015, Jul; 22(7):1113–23. doi: 10.1111/ene.12716. Epub 2015 Apr 22. PubMed PMID:25904020.

Zivadinov

Havrdova

Bergsland

. Thalamic atrophy is associated with development of clinically definite multiple sclerosis. Radiology 2013; 268: 831–841.

Kalincik

Vaneckova

Tyblova

. Volumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study. PLoS One 2012; 7: e50101.

10.

Uher

Horakova

Bergsland

. MRI correlates of disability progression in patients with CIS over 48 months. Neuroimage Clin 2014; 6: 312–319.

11.

Zivadinov

. Steroids and brain atrophy in multiple sclerosis. J Neurol Sci 2005; 233: 73–81.

12.

Dwyer

Bergsland

Zivadinov

. Improved longitudinal gray and white matter atrophy assessment via application of a 4-dimensional hidden Markov random field model. Neuroimage 2014; 90: 207–217.

13.

Smith

De Stefano

Jenkinson

. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001; 25: 466–475.

14.

Reiber

Teut

Pohl

. Paediatric and adult multiple sclerosis: age-related differences and time course of the neuroimmunological response in cerebrospinal fluid. Mult Scler 2009; 15: 1466–1480.

15.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

16.

Reiber

Felgenhauer

. Protein transfer at the blood cerebrospinal fluid barrier and the quantitation of the humoral immune response within the central nervous system. Clin Chim Acta 1987; 163: 319–328.

17.

Rudick

Cookfair

Simonian

. Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. J Neuroimmunol 1999; 93: 8–14.

18.

Calabrese

Federle

Bernardi

. The association of intrathecal immunoglobulin synthesis and cortical lesions predicts disease activity in clinically isolated syndrome and early relapsing–remitting multiple sclerosis. Mult Scler 2012; 18: 174–180.

19.

Durante

Zaaraoui

Rico

. Intrathecal synthesis of IgM measured after a first demyelinating event suggestive of multiple sclerosis is associated with subsequent MRI brain lesion accrual. Mult Scler 2012; 18: 587–591.

20.

Sharief

Thompson

. Intrathecal immunoglobulin M synthesis in multiple sclerosis. Relationship with clinical and cerebrospinal fluid parameters. Brain 1991; 114(Pt 1A): 181–195.

21.

Akaishi

T NK

Suzuki

Mitsuzawa

. Importance of the quotient of albumin, quotient of immunoglobulin G and Reibergram in inflammatory neurological disorders with disease-specific patterns of blood–brain barrier permeability. Neurol Clin Neurosci 2015; 3: 94–100.

22.

Modvig

Degn

Roed

Sørensen

Larsson

Langkilde

Frederiksen

Sellebjerg

Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Mult Scler 2015; 21: 1761–1770.

23.

Lucchinetti

Popescu

Bunyan

. Inflammatory cortical demyelination in early multiple sclerosis. N Engl J Med 2011; 365: 2188–2197.

24.

Howell

Reeves

Nicholas

. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134: 2755–2771.

25.

Hochmeister

Grundtner

Bauer

. Dysferlin is a new marker for leaky brain blood vessels in multiple sclerosis. J Neuropathol Exp Neurol 2006; 65: 855–865.

26.

Kutzelnigg

Lucchinetti

Stadelmann

. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705–2712.

27.

Zivadinov

Reder

Filippi

. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008; 71: 136–144.

28.

Kraus

Ling

Hamm

. Interferon-beta stabilizes barrier characteristics of brain endothelial cells in vitro. Ann Neurol 2004; 56: 192–205.

29.

Jacobs

Beck

Simon

. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000; 343: 898–904.

30.

Sormani

Arnold

De Stefano

. Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis. Ann Neurol 2014; 75: 43–49.

31.

Minagar

Barnett

Benedict

. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology 2013; 80: 210–219.

32.

Zivadinov

Bergsland

Dolezal

. Evolution of cortical and thalamus atrophy and disability progression in early relapsing-remitting MS during 5 years. Am J Neuroradiol 2013; 34: 1931–1939.

33.

Schneider

Euler

Rauer

. Intrathecal IgM-synthesis does not correlate with the risk of relapse in patients with a primary demyelinating event. Eur J Neurol 2007; 14: 907–911.

34.

Stauch

Reiber

Rauchenzauner

. Intrathecal IgM synthesis in pediatric MS is not a negative prognostic marker of disease progression: quantitative versus qualitative IgM analysis. Mult Scler 2011; 17: 327–334.

35.

Magnano

Schirda

Weinstock-Guttman

. Cine cerebrospinal fluid imaging in multiple sclerosis. J Magn Reson Imaging 2012; 36: 825–834.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.33 MB

1.39 MB

Increased albumin quotient (QAlb) in patients after first clinical event suggestive of multiple sclerosis is associated with development of brain atrophy and greater disability 48 months later

Abstract

Background:

Objectives:

Methods:

Results:

Conclusions:

Keywords

Get full access to this article

References

Supplementary Material